Cencora | Pharma solutions’ Post

2025 feels just around the corner. Here are 3 principles guiding us forward: → 𝗔𝗱𝗼𝗽𝘁 𝗮 𝗴𝗿𝗼𝘄𝘁𝗵 𝗺𝗶𝗻𝗱𝘀𝗲𝘁: Every challenge is an oppotunity.   → 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗲: Success is built on teamwork with our people and partners.   → 𝗙𝗼𝗰𝘂𝘀 𝗼𝗻 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲: Every decision we make is for long-term impact. ↳ Building a pharmaceutical facility is more than just construction; it’s about laying the groundwork for:   ✅ Quality ✅ Innovation ✅ Community impact   At ITICO Pharma, we’re committed to creating a space that upholds the highest standards in pharmaceutical manufacturing. → What principles are driving your 2025 plans? Let’s share ideas!  

In this blog, two MMIT solution consultants share four steps smaller pharma companies and biotechs can take to ensure commercialization success—even with limited resources. What exactly does it mean to get an early start on commercialization? MMIT’s Ryan Witherington and Olga Yaremchuk explain what smaller pharma companies should do in Phase I or II to set the stage for market entry: https://ow.ly/cMKv50RovZQ #BiotechTips #PharmaSolutions #MarketEntry #PharmaInsights #PharmaConsulting #BiotechStrategy

Here are four tips for smaller manufacturers on how you might approach the journey to commercialization—and come out ahead, despite the obstacles.

As biopharma R&D faces unprecedented challenges, our new report provides key strategies to help companies navigate this complex landscape and advance #PharmaInnovation.

Pharma and biotech’s top R&D spenders in 2023: a $153B total with M&A as a focus https://lnkd.in/gDKg894X At a time when biotech is still counting its losses as a thaw gradually sets in after the long market winter, pharma has been on a tear. M&A took off in Q4 as the industry’s [...]

How can pharma manufacturers stay agile without sacrificing quality or driving up costs? Learn from Merck KGaA, Darmstadt, Germany why a modular production setup with the MTP standard is the answer. 🏭In this webinar, discover how plug-and-play flexibility is reshaping the industry. https://sie.ag/2uoE7D #Pharma #SmartManufacturing #MTP

In this blog, two MMIT solution consultants share four steps smaller pharma companies and biotechs can take to ensure commercialization success—even with limited resources. What exactly does it mean to get an early start on commercialization? MMIT’s Ryan Witherington and Olga Yaremchuk explain what smaller pharma companies should do in Phase I or II to set the stage for market entry: https://ow.ly/221C50Rrgmq. #BiotechTips #PharmaSolutions #MarketEntry #PharmaInsights #PharmaConsulting #BiotechStrategy

We support big pharma, small pharma, and in-between pharma! Our team is experienced at jumping into projects and making an immediate impact because... it's what we do! Reach out to book a discovery call. #FusionPharma #RegulatoryConsultancy #RegulatoryAffairs

In this market cycle, Suven Pharma has been a big winner for us at Stalwart Investment Advisors LLP Suven is one of the highest quality businesses in India - massive value addition as depicted by consistent 70%+ gross margins & core RoCE of over 50%. The 2019 demerger of life sciences (loss making) segment gave us a good opportunity to enter. We exited recently at a healthy return, as valuations zoomed up making risk-reward less favourable. More on this in annexed post.

🔬 The Future of Work in Pharma: What’s Ahead in 2025?   The pharmaceutical industry is evolving faster than ever, and the road ahead is filled with both exciting opportunities and new challenges. In our upcoming whitepaper, we’ll be diving into Open Water | People & Change’s key insights from 2024 and explore the trends we’re tracking for 2025.   BUT BEFORE WE DO, we want to hear from YOU! What’s top of mind for you heading into 2025? Which trends or challenges are you preparing for in your organisations?   🚀 Let’s start the conversation! Drop a comment below and share your thoughts.   #Pharma #FutureOfWork #Innovation #Trends2025 #PharmaceuticalIndustry #WorkplaceTransformation